

Special Issue

Telomerase: Role in Health and Aging

Message from the Guest Editor

The history of the prediction, discovery, and study of telomerase has been unfolding before us for over 100 years. Today, we are far less concerned with extending life; instead, increasing the length of a healthy life.

The aim of this Special Issue is to summarize the knowledge of telomerase functions and its role in the pathophysiology of aging-associated diseases and cancer. Topics of the Special Issue include but are not limited to the following:

1. Telomerase and mitochondria, redox regulation
2. Non-canonical functions of telomerase
3. Telomerase, telomeres, SASP
4. Inflamm-aging, senolytics
5. Special role of telomerase in neurons
6. Telomerase and cancer. Features of hTERT repression. Fusion-bridge-breakage mechanism, circular chromosomes, chromothripsis
7. Telomerase, lifespan, body size
8. Telomere position effect
9. Telomeropathies: diskeratosis congenita, interstitial pulmonary fibrosis, etc.
10. Telomere measurement methods. Comparisons
11. G4 structures: role in telomeres and whole genome
12. Splicing hTERT as a regulator

Guest Editor

Prof. Dr. Yegor E. Yegorov

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia

Deadline for manuscript submissions

closed (30 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/70553

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).